Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE;
OTCQX:ATBPF) is pleased to announce the expansion of its Clinical
Advisory Board with the appointment of Canadian rheumatologist J. Carter
Thorne, MD, FRCP(C), FACP, Chief of the Division of Rheumatology and
Director of The Arthritis Program at Southlake Regional Health Centre in
Newmarket, Canada.
Dr. Thorne holds a Fellowship with the Royal College of Physicians in
Internal Medicine and Rheumatology FRCP(C), and is also a Fellow at the
American College of Physicians and American College of Rheumatology FACP.
Dr. Thorne sits on numerous national and international steering and
scientific committees identifying and disseminating outcomes and best
practices in the management of arthritis.
Dr. Thorne is active in clinical research as Principal Investigator with
The Arthritis Program (TAP) Research Group and was secretary-treasurer
and a founding member of the Canadian Rheumatology Research Consortium.
He sits on the Steering and Scientific Committee of the Ontario Best
Practices Research Initiative, and is a founding member and
past-president of the Ontario Rheumatology Association (ORA) and
past-president of the Canadian Rheumatology Association (CRA). At the
international level, Dr. Thorne is the past secretary-treasurer of the
Pan-American League Against Rheumatism (PANLAR), and sits on the
steering committee of the American College of Rheumatology’s CARE
(Continuing Assessment, Review, and Evaluation) Program.
Antibe’s Chief Science Officer, Dr. John Wallace, remarked: “We are
excited and honoured to have Dr. Thorne, a well-respected physician and
researcher join our Clinical Advisory Board. Through his involvement in
multiple initiatives, Dr. Thorne has not only improved the treatment and
care of patients with arthritis but also contributed significantly to
the profession’s enhanced knowledge of arthritis care both in Canada and
around the globe.”
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat
inflammatory conditions such as arthritis, but are associated with
serious and potentially life-threatening side effects, including
gastrointestinal ulceration and bleeding. Antibe’s lead drug,
ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, one of
the most prescribed NSAIDs globally. In pre-clinical testing, ATB-346
exhibited comparable anti-inflammatory activity to naproxen, but with
negligible adverse effects. ATB-346 is presently being evaluated in a
phase I human clinical trial. The Clinical Advisory Board will play a
major role in designing Antibe’s future clinical development program,
aimed at demonstrating the effectiveness and improved safety of ATB-346.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s
technology involves linking a hydrogen sulfide-releasing molecule to an
existing drug to produce a patented, improved medicine. Antibe’s lead
drug ATB-346 targets the global need for a safer non-steroidal
anti-inflammatory drug (NSAID) for chronic pain and inflammation.
ATB-352, the second drug in Antibe’s pipeline, targets the urgent global
need for a safer analgesic for severe acute pain.
www.antibethera.com
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Important
Note on Forward Looking Statements
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20141218005169r1&sid=ntxv4&distro=nx&lang=en)
Copyright Business Wire 2014